Question 1

What is Relmada Therapeutics?

Accepted Answer

Relmada Therapeutics is a Company.

Question 2

How often does Relmada Therapeutics appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Relmada Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jun 11, 2026.

Question 4

When was Relmada Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 16, 2026.

Question 5

What is Relmada Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Relmada Therapeutics in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Relmada Therapeutics?

Accepted Answer

Relmada_Therapeutics appoints Michael_Quirk (Jun 11, 2026, 6 articles).

Question 8

How did the "Relmada_Therapeutics appoints Michael_Quirk" event impact Relmada Therapeutics?

Accepted Answer

Relmada Therapeutics appointed Michael Quirk>>> as Senior Advisor for its sepranolone program, aiming to leverage his expertise to advance the drug's development for CNS disorders. This appointment is expected to strengthen the company's research and development efforts.

Question 9

How did the "Relmada Q2 2026 earnings call" event impact Relmada Therapeutics?

Accepted Answer

Relmada is the subject of the event, announcing its Q2 2026 earnings call. The event provides a platform to update investors on financials and clinical progress.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.